TherapeuticsMD (NASDAQ:TXMD) Stock Price Down 5.2%

TherapeuticsMD Inc (NASDAQ:TXMD)’s stock price fell 5.2% during trading on Tuesday . The stock traded as low as $3.56 and last traded at $3.63, 2,719,248 shares changed hands during trading. A decline of 15% from the average session volume of 3,195,163 shares. The stock had previously closed at $3.83.

Several research firms have recently commented on TXMD. ValuEngine raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Jefferies Financial Group decreased their target price on shares of TherapeuticsMD from $4.00 to $3.00 and set a “hold” rating for the company in a research report on Monday, July 15th. BidaskClub raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Wednesday, September 11th. JPMorgan Chase & Co. decreased their target price on shares of TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, June 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of TherapeuticsMD in a research report on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. TherapeuticsMD has an average rating of “Buy” and a consensus price target of $9.16.

The firm has a market capitalization of $923.87 million, a PE ratio of -6.15 and a beta of 1.69. The firm’s fifty day moving average is $3.00 and its two-hundred day moving average is $3.44. The company has a debt-to-equity ratio of 24.29, a current ratio of 5.17 and a quick ratio of 4.99.



TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). TherapeuticsMD had a negative return on equity of 212.57% and a negative net margin of 913.07%. The firm had revenue of $6.08 million for the quarter, compared to analysts’ expectations of $5.12 million. During the same quarter last year, the firm posted ($0.15) earnings per share. The firm’s revenue for the quarter was up 60.0% compared to the same quarter last year. As a group, equities research analysts predict that TherapeuticsMD Inc will post -0.73 EPS for the current fiscal year.

In other news, CEO Robert G. Finizio purchased 52,405 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were acquired at an average cost of $2.96 per share, for a total transaction of $155,118.80. Following the completion of the acquisition, the chief executive officer now owns 18,166,559 shares in the company, valued at $53,773,014.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Angus C. Russell purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were purchased at an average price of $2.77 per share, for a total transaction of $27,700.00. Following the completion of the acquisition, the director now owns 93,500 shares of the company’s stock, valued at approximately $258,995. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 170,549 shares of company stock worth $493,167. 18.91% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in TXMD. Moors & Cabot Inc. purchased a new position in TherapeuticsMD in the second quarter valued at about $25,000. Moloney Securities Asset Management LLC purchased a new position in TherapeuticsMD in the second quarter valued at about $27,000. Highland Private Wealth Management purchased a new position in TherapeuticsMD in the second quarter valued at about $28,000. H D Vest Advisory Services purchased a new position in TherapeuticsMD in the second quarter valued at about $34,000. Finally, Advisor Group Inc. boosted its stake in TherapeuticsMD by 73.2% in the second quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock valued at $36,000 after acquiring an additional 5,900 shares during the last quarter. Institutional investors and hedge funds own 77.99% of the company’s stock.

TherapeuticsMD Company Profile (NASDAQ:TXMD)

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Recommended Story: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.